Protagonist Therapeutics stock gets USD 300.0 million buyback approval

Published on 09/29/2026 at 14:03 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Protagonist Therapeutics stock gets a USD 300.0 million buyback authorization dated September 8, 2026. Q2 revenue reached USD 213.47 million.

PTGX, US74374T1097, Illustration mit AI erstellt.

Protagonist Therapeutics (ISIN US74374T1097) received authorization for a USD 300.0 million share repurchase program on September 8, 2026, giving the biotechnology company a new capital allocation lever after a sharply stronger second quarter. The program is discretionary and does not require the company to repurchase a fixed number of shares, Yahoo Finance reported.

Buyback backed by cash

Protagonist said the repurchases may be funded by cash, marketable securities, royalties and collaboration payments linked to Takeda and Johnson and Johnson. As of June 30, 2026, cash, cash equivalents and marketable securities totaled USD 849.5 million, while the company had also earned a USD 200.0 million opt-out payment and a USD 75.0 million milestone from Takeda in August.

The expected Takeda payments total USD 275.0 million and are due in the fourth quarter of 2026, according to StockTitan. That funding profile makes the buyback announcement more than a balance-sheet headline, but the authorization still leaves timing and execution dependent on market conditions and royalty receipts.

Q2 profit shows a sharp swing

For Q2 2026, Protagonist reported USD 213.47 million in revenue and diluted EPS of USD 2.29, compared with a USD 2.27 consensus estimate. Revenue increased 3,746.80 percent year over year, while net income reached USD 162.85 million, figures reported by MarketBeat. The comparison with consensus is important because the earnings jump came alongside collaboration economics and milestone-related revenue, not only recurring product sales.

BMO lifts target to USD 190.00

On September 1, 2026, BMO Capital Markets raised its Protagonist price target from USD 178.00 to USD 190.00 and maintained an outperform rating, according to MarketBeat. The same report described a consensus Moderate Buy view based on 16 Buy ratings and two Holds, while the USD 190.00 target stood above the reported consensus target of USD 147.13.

Market value and yearly range

On September 25, 2026, Protagonist had a market capitalization of USD 9.0 billion and a 52-week range of USD 54.50 to USD 160.81 on Nasdaq. The company combines commercial royalty streams with a peptide medicine pipeline, leaving future valuation tied to both cash generation and development milestones.